Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Inventory (2017 - 2026)

Neurocrine Biosciences filings provide 9 years of Inventory readings, the most recent being $69.0 million for Q4 2025.

  • On a quarterly basis, Inventory rose 20.21% to $69.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.0 million, a 20.21% increase, with the full-year FY2025 number at $69.0 million, up 20.21% from a year prior.
  • Inventory hit $69.0 million in Q4 2025 for Neurocrine Biosciences, roughly flat from $69.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $69.3 million in Q3 2025 to a low of $25.5 million in Q3 2021.
  • Median Inventory over the past 5 years was $36.0 million (2022), compared with a mean of $40.7 million.
  • Biggest five-year swings in Inventory: decreased 22.16% in 2023 and later skyrocketed 59.03% in 2024.
  • Neurocrine Biosciences' Inventory stood at $30.5 million in 2021, then increased by 15.08% to $35.1 million in 2022, then increased by 9.12% to $38.3 million in 2023, then soared by 49.87% to $57.4 million in 2024, then grew by 20.21% to $69.0 million in 2025.
  • The last three reported values for Inventory were $69.0 million (Q4 2025), $69.3 million (Q3 2025), and $56.9 million (Q2 2025) per Business Quant data.